US-listed medical technology company Safeguard Scientifics is preparing for its second flotation of a portfolio company, NuPathe for $86.25m.

US-listed medical technology company Safeguard Scientifics is preparing for its second flotation of a portfolio company, NuPathe for $86.25m.

The US-based developer of drugs for the central nervous system, is expected to have its initial public offering (IPO) on the Nasdaq stock exchange, with Lazard Capital Markets and Leerink Swann serving as co-lead underwriters, according to news provider pehub.com.

Gary Kurtzman, vice president and a managing director of the life sciences group at Safeguard, led NuPathe’s $15m A round of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?